학술논문
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups.
Document Type
Article
Author
Perrone, Fabiana; Mazzaschi, Giulia; Minari, Roberta; Verzè, Michela; Azzoni, Cinzia; Bottarelli, Lorena; Nizzoli, Rita; Pluchino, Monica; Altimari, Annalisa; Gruppioni, Elisa; Sperandi, Francesca; Andrini, Elisa; Guaitoli, Giorgia; Bertolini, Federica; Barbieri, Fausto; Bettelli, Stefania; Longo, Lucia; Pagano, Maria; Bonelli, Candida; Tagliavini, Elena
Source
Subject
*LUNG cancer prognosis
*LUNG cancer
*RESEARCH
*ADENOCARCINOMA
*GENETIC mutation
*SCIENTIFIC observation
*CANCER chemotherapy
*METASTASIS
*RETROSPECTIVE studies
*TREATMENT effectiveness
*SURVIVAL analysis (Biometry)
*DESCRIPTIVE statistics
*PROGRESSION-free survival
*IMMUNOTHERAPY
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2072-6694
Abstract
Simple Summary: Around 2–4% of lung adenocarcinoma harbors BRAF mutations. Dabrafenib and Trametinib represent the first treatment-choice for BRAF V600Emut NSCLC, regardless of the line of therapy, while non-V600Emut receive standard immunotherapy or chemo-immunotherapy. Our real-life multicenter study on 44 BRAF mutant NSCLC responds to the urgent need to characterize this subset of patients in-depth, potentially offering new valuable biological and clinical insights. We specifically focused on similarities/discrepancies between V600E and non-V600E populations, providing consistent data about clinicopathologic characteristics, treatment response, and survival outcome. Introduction: BRAF mutation involved 2–4% of lung adenocarcinoma. Differences in clinicopathologic features and patient outcome exist between V600E and non-V600E BRAF mutated NSCLC. Thus, we sought to assess the frequency and clinical relevance of BRAF mutations in a real-life population of advanced-NSCLC, investigating the potential prognostic significance of distinct genetic alterations. Materials and Methods: The present multicenter Italian retrospective study involved advanced BRAF mutant NSCLC. Complete clinicopathologic data were evaluated for BRAF V600E and non-V600E patients. Results: A total of 44 BRAFmut NSCLC patients were included (V600E, n = 23; non-V600E, n = 21). No significant differences in survival outcome and treatment response were documented, according to V600E vs. non-V600E mutations, although a trend towards prolonged PFS was observed in the V600E subgroup (median PFS = 11.3 vs. 6.0 months in non-V600E). In the overall population, ECOG PS and age significantly impacted on OS, while bone lesions were associated with shorter PFS. Compared to immunotherapy, first-line chemotherapy was associated with longer OS in the overall population, and especially in the BRAF V600E subtype. Conclusions: Here, we report on real-life data from a retrospective cohort of advanced-NSCLC harboring BRAF alterations. Our study offers relevant clues on survival outcome, therapeutic response, and clinicopathologic correlations of BRAF-mutant NSCLC. [ABSTRACT FROM AUTHOR]